$CRDF has generated 9 mentions over the past 12 months from 2 distinct FinTwit voices, with discussion concentrated in the biotech category. The first mention appeared on July 29, 2025, and mentions continued through July 30, 2025. @jacobplieth (@jacobplieth) dominated the conversation with 8 mentions, while @adamfeuerstein (@adamfeuerstein ✡️) contributed 1 mention during this period.

The most recent activity on July 30, 2025 focused on Cardiff Oncology's onvansertib phase 2 trial data. @jacobplieth noted that $CRDF opened down 20% and referenced baseline imbalances alongside declining overall response rate (ORR) data from the trial. A separate post from @jacobplieth highlighted clarification around first-line indication details for the company's program.